CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 658.5	$ 597.3
Trade receivables, net	2,708.4	2,686.9
Inventories, net	1,300.1	1,256.6
Prepaid expenses and other current assets	1,006.8	966.4
Total current assets	5,673.8	5,507.2
Property, plant and equipment, net	1,462.0	1,441.8
Intangible assets, net	20,509.4	23,083.0
Goodwill	17,450.1	18,552.8
Deferred tax assets, net	452.3	156.0
Other long-term assets, net	213.6	223.7
Total assets	45,761.2	48,964.5
Current liabilities:
Accounts payable	358.7	433.7
Accrued and other current liabilities	3,391.8	3,859.1
Acquisition-related contingent consideration	87.3	196.8
Current portion of long-term debt	59.0	823.0
Total current liabilities	3,896.8	5,312.6
Acquisition-related contingent consideration	898.0	959.1
Long-term debt	30,386.2	30,265.4
Pension and other benefit liabilities	190.3	190.4
Liabilities for uncertain tax positions	112.3	120.2
Deferred tax liabilities, net	5,839.0	5,902.4
Other long-term liabilities	165.0	184.6
Total liabilities	41,487.6	42,934.7
Commitments and contingencies
Equity
Common shares, no par value, unlimited shares authorized, 347,669,423 and 342,926,531 issued and outstanding at September 30, 2016 and December 31, 2015, respectively	10,034.4	9,897.4
Additional paid-in capital	325.9	304.9
Accumulated deficit	(4,614.1)	(2,749.7)
Accumulated other comprehensive loss	(1,578.9)	(1,541.6)
Total Valeant Pharmaceuticals International, Inc. shareholders’ equity	4,167.3	5,911.0
Noncontrolling interest	106.3	118.8
Total equity	4,273.6	6,029.8
Total liabilities and equity	$ 45,761.2	$ 48,964.5